Advice
Following a re-submission
anidulafungin (Ecalta®) is accepted for restricted use within NHS Scotland for the treatment of invasive candidiasis in adult non-neutropenic patients.
Anidulafungin has been shown to be at least as effective as an alternative antifungal in a study of patients, the majority of whom had candidaemia. Its use is restricted to patients who are unable to tolerate fluconazole or have invasive candidiasis that is resistant to fluconazole.
Download detailed advice96KB (PDF)
Medicine details
- Medicine name:
- anidulafungin (Ecalta)
- SMC ID:
- 465/08
- Indication:
- Invasive candidiasis in adult non-neutropenic patients
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Infections
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 10 November 2008